Helicobacter pylori
Conditions
Interventions
Experimental group:10mg Bid for breakfast and 0.5-1h before dinner, 3.2 g Tid for rabeprazole, 0.5-1h before lunch and 0.5-1h before dinner, 1g Bid for Amoxicillin, take Clarithromycin 500mg Bid at br
Control group: Rabeprazole 10 mg Bid at breakfast and 0.5-1 h before dinner, bismuth complex 2.6 g tid at breakfast, lunch and 0.5-1 h before dinner, Amoxicillin 1g Bid, take Clarithromycin 500mg Bid
Sponsors
Civil Aviation General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) For those aged 18-75 (including the boundary values at both ends), gender is not limited; 2) The result of 13C or 14C urea breath test is H Those with positive pylori infection; 3) People with symptoms of upper digestive tract, such as epigastric pain, acid regurgitation, heartburn, epigastric distension, nausea, one or more. 4) Before screening, subjects have fully understood the study and voluntarily signed a written informed consent form.
Exclusion criteria
Exclusion criteria: 1) The first half year of screening has passed the standard H Pylori eradication therapists; 2) Those who have used proton pump inhibitors or H2 receptor antagonists, antibiotics, bismuth agents, and gastric mucosal protective agents within 4 weeks before screening; 3) Those who have used macrolides and penicillins repeatedly (5 times or more within one year) or for a long time (10 weeks or more); 4) Those who are allergic to any component of the test related drugs (bismuth, rabeprazole, antibiotics [penicillin (amoxicillin, etc.), macrolides (clarithromycin, etc.), and Qingwei Zhitong pellets]) or have contraindications to the test related drugs; 5) Patients with malignant tumor or history of esophageal and gastrointestinal surgery; 6) Patients with pyloric obstruction, gastric perforation and Zoe Ai syndrome; 7) Patients with acute upper gastrointestinal bleeding within 1 week before screening; 8) Those who need to take drugs that affect anticoagulation system, coagulation system, fibrinolysis system or non steroidal anti-inflammatory drugs during the test; 9) Other serious heart, liver and kidney dysfunction (ALT, AST>1.5 times the upper limit of normal value or Cr>the upper limit of normal value), anemia (Hb<90g/L) and other serious hematopoiesis and coagulation system diseases can not be effectively controlled; 10) Pregnant or lactating women, or subjects with positive pregnancy test, or with birth plan within 6 months after screening test; 11) Those who have a history of drug or alcohol abuse within one year before screening, or do not agree to abide by the provisions of the test (including prohibition of drinking) during the study period; 12) The researcher comprehensively judged that it was not suitable to participate in the clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 13C urea breath test; | — |
Countries
China
Contacts
Public ContactJianping Cheng
Civil Aviation General Hospital
Outcome results
None listed